Finance

Lists
Why is SLDB down 2.29%?
Dive Deeper
SLDB:NASDAQ
Solid Biosciences Inc
$6.84
-2.29%
(-0.16) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SLDB...
Open
$7.00
High
$7.05
Low
$6.56
Mkt. cap
763.42M
Avg. vol.
1.38M
Volume
975.45K
52-wk high
$11.45
52-wk low
$4.16
EPS
-$1.78
Beta
2.65
Shares outstanding
111.61M
No. of employees
121
Open
$7.00
High
$7.05
Low
$6.56
Mkt. cap
763.42M
Avg. vol.
1.38M
Volume
975.45K
52-wk high
$11.45
52-wk low
$4.16
EPS
-$1.78
Beta
2.65
Shares outstanding
111.61M
No. of employees
121
News stories
From web sources and news partners
About Solid Biosciences Inc
CEO-
Employees121
Founded2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitesolidbio.com
Analyst ratings
Based on 11 analysts giving stock ratings to SLDB in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for SLDB in the last 3 months.
Highest
Current $6.84
$26.00 (+280.12%)
Average
$18.00 (+163.16%)
Lowest
$11.00 (+60.82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Maintained
$11.00
+60.8%
11/12/2026
Alethia Young
William Blair
Buy
Initiated
$11.00
+60.8%
11/09/2026
Luca Issi
RBC Capital
Buy
Maintained
$18.00
+163.2%
11/04/2026
Daniel Clark
Leerink Partners
Buy
Reiterated
$20.00
+192.4%
11/05/2026
Laura Chico
Wedbush
Buy
Maintained
$15.00
+119.3%
11/05/2026
Biren Amin
Piper Sandler
Buy
Maintained
$18.00
+163.2%
11/05/2026
Joon Lee
UBS
Buy
Maintained
$20.00
+192.4%
11/05/2026
Arthur He CFA
H.C. Wainwright
Buy
Maintained
$25.00
+265.5%
11/05/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$26.00
+280.1%
09/15/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$20.00
+192.4%
09/16/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$14.00
+104.7%
09/10/2026
Danielle Brill
Truist Financial
Buy
Initiated
$20.00
+192.4%
08/21/2026
Gil Blum
Needham
Buy
Maintained
$19.00
+177.8%
08/07/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$15.00
+119.3%
05/13/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
03/20/2026
Debjit Chattopadhyay
Guggenheim
Buy
Initiated
$26.00
+280.1%
03/20/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$0.36 / -$0.41
+13.14%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38.14M
46.14M
44.26M
43.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.27M
11.17M
13.12M
14.06M
Operating expense
49.40M
57.31M
57.38M
57.66M
Total operating expenses
49.40M
57.31M
57.38M
57.66M
Operating income
-49.40M
-57.31M
-57.38M
-57.66M
Other non operating income
-2.44M
-1.49M
-636.00K
364.00K
EBT including unusual items
-49.79M
-56.74M
-54.80M
-53.95M
EBT excluding unusual items
-49.79M
-56.74M
-54.80M
-53.95M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-49.79M
-56.74M
-54.80M
-53.95M
Net profit margin
-
-
-
-
Earnings per share
-0.53
-0.52
-0.38
-0.36
Interest and investment income
2.05M
2.06M
3.22M
3.34M
Interest expense
-
-
-
-
Net interest expenses
2.05M
2.06M
3.22M
3.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-48.94M
-56.91M
-56.99M
-57.24M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps